NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $209.77
  • Forecasted Upside: 49.15 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
▼ -2.11 (-1.48%)

This chart shows the closing price for JAZZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jazz Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JAZZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JAZZ

Analyst Price Target is $209.77
▲ +49.15% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $209.77, with a high forecast of $250.00 and a low forecast of $174.00. The average price target represents a 49.15% upside from the last price of $140.64.

This chart shows the closing price for JAZZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 15 investment analysts is to buy stock in Jazz Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 17 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 17 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 17 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 18 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/20/2021SVB LeerinkLower Price TargetOutperform$230.00 ➝ $200.00Low
12/17/2021Needham & Company LLCLower Price TargetBuy$220.00 ➝ $215.00Medium
11/18/2021The Goldman Sachs GroupInitiated CoverageBuyHigh
10/8/2021Morgan StanleyLower Price TargetEqual Weight$176.00 ➝ $174.00Low
10/5/2021CitigroupInitiated CoverageBuy$200.00Medium
9/22/2021Needham & Company LLCInitiated CoverageBuy$220.00High
8/16/2021HC WainwrightLower Price TargetBuy$220.00 ➝ $210.00Low
7/23/2021Royal Bank of CanadaBoost Price TargetOutperform$190.00 ➝ $216.00Low
7/22/2021SVB LeerinkReiterated RatingBuyLow
7/6/2021Jefferies Financial GroupInitiated CoverageBuy$220.00Low
6/22/2021BarclaysBoost Price TargetOverweight$235.00 ➝ $250.00Low
6/21/2021HC WainwrightBoost Price TargetBuy$212.00 ➝ $220.00Low
6/18/2021SVB LeerinkBoost Price TargetOutperform$210.00 ➝ $230.00Low
5/24/2021Piper SandlerReiterated RatingBuy$214.00Low
5/19/2021JPMorgan Chase & Co.Initiated CoverageOverweightLow
5/17/2021HC WainwrightBoost Price TargetBuy$207.00 ➝ $212.00Medium
5/9/2021SVB LeerinkReiterated RatingBuyLow
5/7/2021Jefferies Financial GroupReiterated RatingBuyLow
4/21/2021Cantor FitzgeraldBoost Price TargetOverweight$185.00 ➝ $198.00Medium
4/14/2021Stifel NicolausBoost Price TargetBuy$195.00 ➝ $202.00High
4/1/2021Morgan StanleyBoost Price TargetEqual Weight$162.00 ➝ $176.00Low
3/15/2021SVB LeerinkReiterated RatingOutperformMedium
3/1/2021UBS GroupBoost Price TargetBuy$174.00 ➝ $228.00Low
2/25/2021SVB LeerinkLower Price TargetOutperform$213.00 ➝ $210.00Medium
2/24/2021CowenBoost Price TargetOutperform$190.00 ➝ $200.00High
2/24/2021Jefferies Financial GroupBoost Price TargetBuy$209.00 ➝ $214.00High
2/24/2021Piper SandlerBoost Price TargetOverweight$175.00 ➝ $205.00High
2/5/2021HC WainwrightBoost Price TargetBuy$195.00 ➝ $207.00High
2/3/2021Piper SandlerUpgradeNeutral ➝ Overweight$150.00 ➝ $175.00High
1/29/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$177.00 ➝ $162.00High
12/15/2020UBS GroupInitiated CoverageBuy$174.00High
11/3/2020Wells Fargo & CompanyBoost Price TargetOverweight$171.00 ➝ $184.00High
11/3/2020Royal Bank of CanadaBoost Price TargetOutperform$170.00 ➝ $180.00High
11/3/2020BarclaysBoost Price TargetOverweight$225.00 ➝ $233.00High
11/3/2020SVB LeerinkBoost Price TargetOutperform$194.00 ➝ $202.00High
11/3/2020HC WainwrightBoost Price TargetBuy$185.00 ➝ $195.00High
10/26/2020BarclaysBoost Price TargetOverweight$205.00 ➝ $225.00Low
10/20/2020Truist FinancialBoost Price Target$157.00 ➝ $175.00Medium
10/9/2020Jefferies Financial GroupBoost Price TargetBuy$151.00 ➝ $188.00Low
10/9/2020SVB LeerinkBoost Price TargetOutperform$164.00 ➝ $182.00Low
10/9/2020HC WainwrightBoost Price TargetBuy$175.00 ➝ $185.00Low
9/14/2020Royal Bank of CanadaBoost Price Target$160.00 ➝ $170.00Low
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$175.00Medium
9/14/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$128.00Medium
8/13/2020Wells Fargo & CompanyBoost Price TargetOverweight$150.00 ➝ $171.00Low
8/6/2020BarclaysReiterated RatingBuyHigh
8/6/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$177.00High
7/30/2020OppenheimerInitiated CoverageOutperformHigh
7/28/2020Wolfe ResearchUpgradePeer Perform ➝ OutperformLow
7/23/2020HC WainwrightUpgradeNeutral ➝ Buy$145.00 ➝ $166.00Medium
6/23/2020BarclaysBoost Price TargetOverweight$183.00 ➝ $195.00Low
6/18/2020Bank of AmericaBoost Price TargetBuy$165.00 ➝ $167.00Low
6/1/2020SVB LeerinkBoost Price TargetOutperform$160.00 ➝ $169.00Low
5/6/2020SunTrust BanksLower Price TargetBuy$155.00 ➝ $153.00Medium
5/6/2020OppenheimerReiterated RatingBuy$132.00Medium
5/6/2020SVB LeerinkLower Price TargetOutperform$169.00 ➝ $160.00Medium
5/6/2020BMO Capital MarketsLower Price TargetPositive ➝ Outperform$205.00 ➝ $193.00High
5/6/2020Piper SandlerLower Price TargetNeutral$127.00 ➝ $113.00High
4/30/2020Wells Fargo & CompanyLower Price TargetOverweight$189.00 ➝ $162.00Low
4/30/2020OppenheimerLower Price TargetOutperform$154.00 ➝ $141.00Low
4/6/2020Jefferies Financial GroupInitiated CoverageBuy$149.00High
4/2/2020Morgan StanleyLower Price TargetEqual Weight$147.00 ➝ $109.00Medium
3/30/2020Royal Bank of CanadaLower Price Target$164.00 ➝ $174.00Medium
3/23/2020Bank of AmericaLower Price TargetBuy$178.00 ➝ $163.00High
3/12/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$175.00 ➝ $166.00High
2/27/2020SunTrust BanksLower Price TargetBuy$171.00 ➝ $166.00High
2/26/2020OppenheimerLower Price Target$183.00 ➝ $154.00High
2/26/2020Piper SandlerLower Price Target$142.00 ➝ $129.00High
2/26/2020BMO Capital MarketsLower Price TargetOutperform$208.00 ➝ $205.00High
2/26/2020Royal Bank of CanadaReiterated RatingOutperform$164.00High
2/26/2020CowenLower Price TargetOutperform$200.00 ➝ $165.00High
2/26/2020JPMorgan Chase & Co.Boost Price TargetOverweight$173.00 ➝ $183.00High
1/31/2020SunTrust BanksReiterated RatingBuy$166.00 ➝ $171.00Low
1/22/2020Wells Fargo & CompanyBoost Price TargetOverweight$186.00 ➝ $189.00Low
1/8/2020The Goldman Sachs GroupInitiated CoverageNeutral$153.00Medium
12/3/2019Wells Fargo & CompanyBoost Price TargetOutperform$168.00 ➝ $186.00High
12/2/2019BarclaysBoost Price TargetOverweight$182.00 ➝ $200.00Low
11/11/2019HC WainwrightReiterated RatingHold$147.00Medium
11/11/2019Evercore ISIReiterated RatingBuyMedium
11/7/2019BarclaysReiterated RatingBuy$182.00Medium
10/14/2019Sanford C. BernsteinReiterated RatingMarket Perform$150.00Low
9/26/2019OppenheimerSet Price TargetBuy$176.00Low
8/21/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$205.00 ➝ $142.00High
8/14/2019Wells Fargo & CompanyReiterated RatingBuyLow
8/12/2019Evercore ISIReiterated RatingBuyMedium
8/8/2019HC WainwrightReiterated RatingHold$147.00Low
8/7/2019BarclaysBoost Price TargetOverweight$164.00 ➝ $180.00High
7/8/2019OppenheimerSet Price TargetBuy$176.00Low
7/3/2019Royal Bank of CanadaSet Price TargetBuy$184.00Low
7/3/2019BarclaysSet Price TargetBuy$164.00Low
7/3/2019BMO Capital MarketsSet Price TargetBuy$208.00Low
7/3/2019MizuhoSet Price TargetHold$148.00Low
6/17/2019Wells Fargo & CompanyReiterated RatingBuyLow
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$164.00Low
5/28/2019Piper Jaffray CompaniesSet Price TargetBuy$202.00Low
5/10/2019HC WainwrightReiterated RatingHold$153.00Low
5/8/2019MizuhoBoost Price TargetNeutral$146.00 ➝ $148.00High
5/8/2019BMO Capital MarketsBoost Price TargetOutperform$206.00 ➝ $208.00High
3/27/2019MizuhoReiterated RatingNeutral ➝ Hold$137.00 ➝ $147.00Medium
3/26/2019Cantor FitzgeraldReiterated RatingBuy$185.00Medium
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$163.00Medium
3/19/2019Wells Fargo & CompanySet Price TargetBuy$162.00Low
3/18/2019Royal Bank of CanadaSet Price TargetBuy$184.00Low
3/8/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $135.00Medium
2/27/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$199.00 ➝ $206.00Medium
2/26/2019Cantor FitzgeraldSet Price TargetBuy$185.00Low
2/13/2019CowenReiterated RatingBuy$200.00Medium
2/12/2019Cantor FitzgeraldReiterated RatingBuy$185.00Medium
1/4/2019Cantor FitzgeraldSet Price TargetBuy$201.00Low
12/23/2018Wells Fargo & CompanyReiterated RatingBuyMedium
12/23/2018OppenheimerSet Price TargetBuy$180.00Medium
12/14/2018Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
12/11/2018OppenheimerInitiated CoverageBuy$180.00 ➝ $180.00Low
11/28/2018Morgan StanleySet Price TargetHold$168.00Low
11/20/2018MizuhoLower Price TargetNeutral$157.00Low
11/14/2018HC WainwrightReiterated RatingHold$161.00Medium
11/8/2018B. RileyLower Price TargetBuy ➝ Buy$219.00 ➝ $190.00Medium
11/7/2018CowenSet Price TargetBuy$200.00High
11/7/2018Wells Fargo & CompanyReiterated RatingBuyHigh
11/7/2018Royal Bank of CanadaSet Price TargetBuy$184.00High
11/7/2018Piper Jaffray CompaniesSet Price TargetBuy$208.00High
11/6/2018Cantor FitzgeraldReiterated RatingBuy$201.00High
10/19/2018Piper Jaffray CompaniesSet Price TargetBuy$213.00Low
10/15/2018MizuhoReiterated RatingNeutral$173.00High
8/17/2018SVB LeerinkBoost Price TargetOutperform$200.00 ➝ $210.00Low
8/15/2018Wells Fargo & CompanyReiterated RatingBuy$182.00 ➝ $195.00Medium
8/9/2018HC WainwrightReiterated RatingHold$167.00Low
8/8/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$201.00 ➝ $206.00Medium
8/8/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$180.00 ➝ $205.00High
8/8/2018Piper Jaffray CompaniesReiterated RatingBuy$213.00High
8/7/2018Cantor FitzgeraldSet Price TargetBuy$203.00High
7/13/2018Evercore ISIReiterated RatingBuyLow
7/11/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$183.00Low
7/10/2018CitigroupBoost Price TargetBuy ➝ Buy$162.00 ➝ $205.00Low
7/8/2018Wells Fargo & CompanyReiterated RatingBuyLow
7/2/2018Wells Fargo & CompanyReiterated RatingBuyLow
6/26/2018B. RileyBoost Price TargetBuy ➝ Buy$211.00 ➝ $219.00Low
6/1/2018Royal Bank of CanadaSet Price TargetBuy$194.00Low
5/15/2018Wells Fargo & CompanySet Price TargetOutperform$176.00 ➝ $182.00Low
5/10/2018B. RileyBoost Price TargetBuy ➝ Buy$206.00 ➝ $211.00Medium
5/9/2018MizuhoReiterated RatingHold$150.00High
5/9/2018HC WainwrightSet Price TargetHold$160.00Low
5/9/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$199.00 ➝ $201.00Medium
4/30/2018Cantor FitzgeraldReiterated RatingBuy$202.00High
3/23/2018HC WainwrightReiterated RatingNeutral$150.00 ➝ $160.00Medium
3/19/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$128.58 ➝ $163.75High
3/1/2018Piper Jaffray CompaniesReiterated RatingBuy$201.00Low
2/28/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$196.00 ➝ $199.00High
2/20/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$164.00 ➝ $170.00Low
1/16/2018B. RileyReiterated RatingBuy$206.00Low
1/16/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$170.00Medium
1/2/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$180.00Low
12/25/2017Wells Fargo & CompanyReiterated RatingBuyLow
12/20/2017B. RileyReiterated RatingBuy$206.00Low
12/10/2017Cantor FitzgeraldReiterated RatingBuy$200.00Low
12/5/2017B. RileyReiterated RatingBuy$206.00Low
12/5/2017MizuhoBoost Price TargetNeutral ➝ Neutral$144.00 ➝ $150.00Low
12/3/2017Cantor FitzgeraldReiterated RatingBuy$200.00Low
11/10/2017HC WainwrightReiterated RatingNeutral ➝ Neutral$144.00 ➝ $150.00N/A
11/8/2017UBS GroupLower Price TargetBuy$172.00 ➝ $168.00N/A
11/8/2017Wells Fargo & CompanyReiterated RatingOutperform$177.00 ➝ $172.00N/A
11/8/2017Royal Bank of CanadaLower Price TargetOutperform$210.00 ➝ $195.00N/A
11/8/2017Royal Bank of CanadaReiterated RatingOutperform$210.00 ➝ $195.00N/A
10/26/2017Stifel NicolausReiterated RatingBuy$190.00N/A
10/23/2017CowenSet Price TargetBuy$190.00N/A
10/21/2017Piper Jaffray CompaniesSet Price TargetBuy$177.00N/A
10/19/2017FBR & Co.Initiated CoverageBuy ➝ Buy$206.00N/A
10/5/2017Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$155.00N/A
9/28/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$165.00Low
9/25/2017UBS GroupReiterated RatingBuy$175.00 ➝ $172.00Low
9/20/2017BMO Capital MarketsReiterated RatingBuy$196.00High
9/18/2017JPMorgan Chase & Co.Reiterated RatingBuy$190.00Low
9/15/2017Royal Bank of CanadaReiterated RatingBuy$210.00Low
8/30/2017Stifel NicolausReiterated RatingBuy$190.00Low
8/29/2017Cantor FitzgeraldReiterated RatingBuyLow
8/29/2017Wells Fargo & CompanyReiterated RatingBuyLow
8/25/2017HC WainwrightInitiated CoverageNeutral ➝ Neutral$144.00Low
8/21/2017CowenSet Price TargetBuy$190.00Low
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$177.00Low
8/10/2017Wells Fargo & CompanyReiterated RatingOutperform$178.00 ➝ $177.00Low
8/9/2017CowenReiterated RatingOutperform$190.00Low
8/9/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$178.00 ➝ $175.00High
8/9/2017Royal Bank of CanadaReiterated RatingBuyLow
8/9/2017Janney Montgomery ScottReiterated RatingBuy$180.00 ➝ $192.00Low
7/17/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$174.00 ➝ $178.00Low
7/14/2017Piper Jaffray CompaniesSet Price TargetBuy$182.00Low
7/14/2017CowenReiterated RatingBuy$190.00Low
7/4/2017MizuhoDowngradeBuy ➝ Neutral$162.00 ➝ $150.00Low
7/4/2017SVB LeerinkBoost Price TargetBuy$169.00 ➝ $170.00Low
7/4/2017Janney Montgomery ScottBoost Price TargetNeutral ➝ Buy$138.00 ➝ $175.00Low
7/4/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$176.00Low
6/27/2017Royal Bank of CanadaSet Price TargetBuy$210.00N/A
6/27/2017Cantor FitzgeraldReiterated RatingBuy$197.00Medium
6/12/2017JPMorgan Chase & Co.Reiterated RatingOverweight$190.00Low
6/7/2017BMO Capital MarketsBoost Price TargetOutperform$192.00 ➝ $196.00Medium
6/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$182.00Medium
6/7/2017CowenReiterated RatingOutperform$190.00Medium
5/31/2017MizuhoLower Price TargetNeutral ➝ Neutral$150.00 ➝ $144.00High
5/22/2017Sanford C. BernsteinSet Price TargetMarket Perform$160.00 ➝ $176.00Low
5/15/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$210.00Low
5/10/2017CowenReiterated RatingOutperform$190.00Low
4/27/2017SVB LeerinkSet Price TargetBuy$179.00Low
4/27/2017Cantor FitzgeraldReiterated RatingBuyHigh
4/8/2017Piper Jaffray CompaniesSet Price TargetBuy$181.00Low
4/7/2017Cantor FitzgeraldBoost Price TargetOverweight$189.00 ➝ $197.00Low
4/7/2017CowenReiterated RatingOutperform$190.00Low
4/6/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$176.00Low
4/6/2017UBS GroupSet Price TargetBuy$168.00N/A
4/6/2017SVB LeerinkSet Price TargetBuy$169.00 ➝ $170.00Low
4/6/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$138.00 ➝ $175.00High
4/6/2017MizuhoDowngradeBuy ➝ Neutral$162.00 ➝ $150.00High
3/21/2017MizuhoReiterated RatingBuy ➝ Buy$152.00 ➝ $162.00Low
3/20/2017SVB LeerinkReiterated RatingOutperformLow
3/20/2017CowenReiterated RatingOutperform ➝ Positive$190.00High
3/20/2017BMO Capital MarketsReiterated RatingOutperform ➝ Positive$192.00High
3/1/2017Cantor FitzgeraldSet Price TargetBuy$187.00N/A
3/1/2017SVB LeerinkSet Price TargetBuy$170.00N/A
3/1/2017Stifel NicolausLower Price TargetBuy$200.00 ➝ $190.00N/A
3/1/2017MizuhoReiterated RatingBuy$152.00N/A
2/22/2017Evercore ISIInitiated CoverageBuy$160.00N/A
2/21/2017MizuhoBoost Price TargetBuy ➝ Buy$127.00 ➝ $152.00N/A
2/16/2017GuggenheimReiterated RatingBuyN/A
2/15/2017BMO Capital MarketsReiterated RatingTop Pick$192.00N/A
2/9/2017GuggenheimReiterated RatingBuy ➝ Buy$200.00N/A
2/8/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$148.00N/A
1/24/2017Cantor FitzgeraldReiterated RatingOverweight$187.00N/A
(Data available from 1/20/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
  • 3 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Jazz Pharmaceuticals logo
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $140.64
Low: $138.92
High: $142.53

50 Day Range

MA: $130.48
Low: $119.87
High: $149.74

52 Week Range

Now: $140.64
Low: $117.64
High: $189.00


675,282 shs

Average Volume

807,194 shs

Market Capitalization

$8.65 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Jazz Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Jazz Pharmaceuticals in the last twelve months: Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for JAZZ.

What is the current price target for Jazz Pharmaceuticals?

13 Wall Street analysts have set twelve-month price targets for Jazz Pharmaceuticals in the last year. Their average twelve-month price target is $209.77, suggesting a possible upside of 49.2%. Barclays PLC has the highest price target set, predicting JAZZ will reach $250.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $174.00 for Jazz Pharmaceuticals in the next year.
View the latest price targets for JAZZ.

What is the current consensus analyst rating for Jazz Pharmaceuticals?

Jazz Pharmaceuticals currently has 1 hold rating and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe JAZZ will outperform the market and that investors should add to their positions of Jazz Pharmaceuticals.
View the latest ratings for JAZZ.

What other companies compete with Jazz Pharmaceuticals?

How do I contact Jazz Pharmaceuticals' investor relations team?

Jazz Pharmaceuticals' physical mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company's listed phone number is (531) 634-7800 and its investor relations email address is [email protected] The official website for Jazz Pharmaceuticals is